FDA Speeds Testing of Two Therapies for Ovarian Cancer Targeting HER2
News
Zymeworks announced that the U.S. Food and Drug Administration (FDA) has granted its lead investigational products, ZW25 and ZW33, orphan drug designation as potential treatments for ovarian cancer (OC). The company’s lead therapeutic ... Read more